undamentalytics Newsletter
Sign in

Gossamer Bio, Inc. (GOSS) stock

Add to watchlist

Add holding +

NASDAQ: GOSS Nasdaq Biotechnology Next results ~November 4, 2026

C+ Fundamentals grade

Gossamer Bio, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Fair value per share

Under review: every model's value for Gossamer Bio, Inc. is far from the share price, which usually points to a data problem (a merger, a share-count change, a one-off) rather than a bargain or a bubble.

Price vs value

Under review: free cash flow after stock pay is not positive. We'll show the comparison once resolved.

Gossamer Bio, Inc. valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Funds89 adding, 85 cuttingOf 26 active managers that changed their stake, 14 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter Gossamer Bio files

Where Gossamer Bio stands after its latest 10-Q

Revenue for the twelve months to June 2026 was $53m, up 32.4% on a year earlier, against a decline of 55.4% a quarter earlier. Free-cash-flow margin rose to -305.2% from -383.7% a year earlier. Operating margin widened to -311.7% from -361.9%. The diluted share count is up 14.3% on a year earlier, which dilutes existing holders. It passes 1 of our 3 financial-health checks.

Our model value for Gossamer Bio is under review, so past values are not shown until it is resolved.

Source: 10-Q filed August 13, 2026 on SEC EDGAR · Financials · Valuation

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~November 4, 2026 (estimated)

Gossamer Bio, Inc.'s trailing-twelve-month revenue grew 32.4% year on year, with a free-cash-flow margin of -305.2%. Where it stands out: change in growth rate of +87.9pp ranks 20 of 172 biotechnology companies we cover.

Current signal Revenue growth accelerating: TTM revenue growth rose to 32.4% (+87.9pp vs the prior quarter).

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Fast growth. Revenue grew 32.4% over the last 12 months, against a median of 12.6% for biotechnology companies we cover.
  • Growth speeding up. The growth rate is 87.9 points higher than a quarter earlier.
  • Margins widening. Operating margin is up 50.2 points on a year ago.
  • Net cash. Cash exceeds long-term debt by $0.0bn.

Things to watch

  • Loss-making. Operating margin is -311.7%: costs exceed revenue.
  • Burning cash. Free cash flow was -305.2% of revenue over the last 12 months.
  • Heavy stock-based pay. Stock pay equals 26.9% of revenue, against a median of 19.2% for biotechnology companies we cover: a real cost that cash-flow figures leave out.
  • Share dilution. Diluted shares rose 14.3% in a year.
  • High sales multiple. The shares trade at 45 times revenue while operating margins remain thin.
  • Volatile shares. Over the past year the shares showed annualised volatility of 140% and a beta of 2.2 against the S&P 500.

Latest results: FY2026 Q2

Filed August 13, 2026
Earnings per share
-$8.17 against an average estimate of -$9.99: beat by 18.2%
Revenue
$9m, down 19.6% on a year earlier
Share reaction
-13.5% in the first session after the results on August 13, 2026, against +0.5% for the S&P 500
Next report
November 4, 2026; average EPS estimate -$3.93

Gossamer Bio's figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day-9.0%
  • 1 week+3.3%
  • 1 month-11.8%
  • This year-96.2%
  • 1 year-95.2%
  • 5 years-99.1%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$53.3M
Operating margin
-311.7%
Net margin
-235.0%
EPS (TTM, diluted)
$-0.49

Growth

Revenue growth
+32.4%
Change in growth rate
+87.9 pts
Share count change
+14.3%

Cash

Free cash flow (TTM)
-$163M
FCF margin
-305.2%
Stock pay % of revenue
26.9%

Earnings

Last results
August 13, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Shareholder vote
  2. Announcement
  3. Announcement
  4. Leadership
  5. Announcement
  6. Announcement
  7. Governance
  8. Governance
  9. Agreement
  10. Results
  11. Results
  12. Leadership

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Gossamer Bio, Inc. valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: free cash flow after stock pay is not positive.

The inputs used by the models below have passed source checks. Individual model values are available below and in the interactive valuator. Their differences are shown explicitly; the platform combined value and recommendation remain withheld.

Valuation models

We value Gossamer Bio, Inc. as an operating company, with every model that fits that kind of business. Cost of equity 10.6%: the 10-year Treasury yield (4.9%) plus a beta of 1.26 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Growth cash-flow model Revenue for this year and next from analysts' consensus, then growth fading to 2.5%; the operating margin moving to profitable peers'; investment needed per dollar of growth from peers; reduced by a failure probability. For young or fast-growing companies. The starting margin is normalized to between -100% and 60%; net margin is a proxy when operating income is not tagged. Uses analysts' consensus estimates (third-party data), not our forecasts. — Does not apply: the projected cash flows don't support a positive value
Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. — Does not apply: This model is withheld pending its input or assumption review.
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: This model is withheld pending its input or assumption review.
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: This model is withheld pending its input or assumption review.
Forward price-to-sales vs peers Next year's consensus sales per share times peers' typical forward price-to-sales; only when earnings are negative. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$0.1 ~$0.1–$0.4 Left out: out of range vs price (0.01x)
Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. — Does not apply: This model is withheld pending its input or assumption review.
Combined value Individual source-checked model scenarios are available. The platform combined value and recommendation remain withheld. — Combined value withheld. Review the individual models and their assumptions.

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Gossamer Bio, Inc. with Biotechnology in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Valuation multiples over time Market data may be delayed

At fiscal year end 2022202320242025Now
Share price$173.60$73.04$72.40$248.00$9.45
Market value$14.7bn$11.1bn$16.4bn$56.7bn$2.4bn
+ Net debt (− = net cash)−$88m−$20m−$46m−$38m−$5m
Enterprise value$14.6bn$11.1bn$16.3bn$56.6bn$2.4bn
Multiples
Price / sales ——142.8xn/m45.4x
Price / earnings —————
Price / free cash flow —————
EV / EBITDA —————

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 4, 2026, after the close. Analysts expect revenue of $12m and EPS of −$3.93 (range −$7.43 to $0.80) for the quarter.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current −$18.01 +70% $41m −16%
Next −$15.61 +13% $17m −59%

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is −47.2% on 90 days ago. In the last 30 days, 1 analyst raised Gossamer Bio, Inc.'s forecast and 0 cut it.

Consensus EPS forecast Gossamer Bio, Inc., last 90 days
−$40.00 −$30.00 −$20.00 −$10.00 $0.00 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: −$34.08 Current fiscal year, 60 days ago: −$31.91 Current fiscal year, 30 days ago: −$14.40 Current fiscal year, 7 days ago: −$16.32 Current fiscal year, Now: −$18.01 −$18.01 Next fiscal year, 90 days ago: −$7.73 Next fiscal year, 60 days ago: −$7.38 Next fiscal year, 30 days ago: −$14.48 Next fiscal year, 7 days ago: −$15.62 Next fiscal year, Now: −$15.61 −$15.61

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago −$34.08−$7.73
60 days ago −$31.91−$7.38
30 days ago −$14.40−$14.48
7 days ago −$16.32−$15.62
Now −$18.01−$15.61

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 −$9.99 −$8.17 +18.2%
Mar 2026 −$13.64 −$16.00 −17.3%
Dec 2025 −$15.65 −$16.80 −7.3%
Sept 2025 −$15.77 −$16.80 −6.5%

Adjusted EPS as companies report it, against the average analyst estimate.

Management guidance

Earnings release, August 13, 2026

No numeric guidance in Gossamer Bio, Inc.'s latest earnings release (filed August 13, 2026). Some companies give their outlook only on the earnings call.

Analyst recommendations

8 analysts, Oct 2026
Buy450%
Hold338%
Sell113%

Monthly trend

  1. Oct 202613318
  2. Sep 202612317
  3. Aug 202612317
  4. Jul 202612317

Counts of recommendations published by analysts covering Gossamer Bio, Inc., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
23.8%
of tradable shares
Days to cover
4.53
at average volume
Short interest, 1 month
+51%
to October 15, 2026
Held by institutions
86%
of shares
Held by insiders
1.4%
of shares
Employees
161
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

What moved the share price

Last 12 months −95.2%

$196.00 on October 31, 2025 to $9.45

ThenNowEffect
Revenue (last 12 months) $40m $53m +32.4%
P/S multiple n/m 45.4x −95.8%
Share count 224m 256m −12.5%

Biggest factor: p/s multiple. Loss-making at one end, so the split uses price/sales.

The effects multiply back to the price change exactly. Results are the last 12 months as known on each date (filings assumed public 45 days after quarter end).

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
GOSS+17%−81%−58%−1%+243%−96%
Industry peers (median)−36%−56%−17%−29%−5%−26%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
GOSS33%33%50%42%67%18%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
GOSS−34%−88%−84%−66%−49%−97%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since February 8, 2019: 100% from December 11, 2019 to October 19, 2026. Getting back needed a 25324% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$8.43 – $303.20
From 52-week high
−96.9%
vs 50-day average
−15.7%
vs 200-day average
−76.5%
Volatility (1 year)
140%
Beta vs S&P 500
2.19

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
6 up, 6 down
typical move ±12.0%
After a week
5 up, 7 down
typical move ±15.3%
After a month
5 up, 7 down
typical move ±27.3%
Results releasedNext dayS&P 500 next day5 days21 days
August 13, 2026 −13.5% +0.5% −11.2% −24.9%
July 27, 2026 +50.7% +0.3% +27.9% +50.7%
May 18, 2026 −41.5% −0.7% −35.3% −47.4%
March 17, 2026 −4.8% −1.1% −24.3% −4.2%
November 5, 2025 +0.4% −0.7% +17.4% +44.8%
August 5, 2025 −8.8% +0.3% −11.1% +15.7%
May 15, 2025 +3.0% +1.1% +14.9% +26.7%
March 13, 2025 +8.2% +0.7% +0.7% −38.4%
November 7, 2024 −0.9% +1.2% −13.2% −13.5%
August 12, 2024 +4.3% +1.7% +18.0% +12.5%
May 7, 2024 −3.3% +0.1% −6.1% −23.2%
March 5, 2024 +4.1% −0.5% −3.4% −26.2%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Gossamer Bio, Inc. in five measures

Fundamentals grade C+
Growth Profitability Cash Balance sheet

Growth, profitability, cash generation and balance sheet are percentiles against the companies we cover in the same industry, from SEC filings (100 = best). Value compares the share price with our modelled value range (50 = at our base value; higher = cheaper). A description of reported data and our model — not a quality score or advice.

Fundamentals

Revenue (TTM) Gossamer Bio, Inc.
$0 $50M $100M $150M FY24 Q1 FY24 Q3 FY25 Q1 FY25 Q3 FY26 Q2 Revenue (TTM), FY24 Q1: $0 Revenue (TTM), FY24 Q2: $95.8M Revenue (TTM), FY24 Q3: $105.3M Revenue (TTM), FY24 Q4: $114.7M Revenue (TTM), FY25 Q1: $124.6M Revenue (TTM), FY25 Q2: $40.2M Revenue (TTM), FY25 Q3: $44.1M Revenue (TTM), FY25 Q4: $48.5M Revenue (TTM), FY26 Q1: $55.5M Revenue (TTM), FY26 Q2: $53.3M $53.3M

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue (TTM)
FY24 Q1 $0
FY24 Q2 $95.8M
FY24 Q3 $105.3M
FY24 Q4 $114.7M
FY25 Q1 $124.6M
FY25 Q2 $40.2M
FY25 Q3 $44.1M
FY25 Q4 $48.5M
FY26 Q1 $55.5M
FY26 Q2 $53.3M
Revenue growth, TTM YoY Gossamer Bio, Inc.
-100% -50% 0% 50% FY25 Q2 FY25 Q3 FY25 Q4 FY26 Q1 FY26 Q2 Revenue growth, TTM YoY, FY25 Q2: -58.0% Revenue growth, TTM YoY, FY25 Q3: -58.2% Revenue growth, TTM YoY, FY25 Q4: -57.7% Revenue growth, TTM YoY, FY26 Q1: -55.4% Revenue growth, TTM YoY, FY26 Q2: 32.4% 32.4%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue growth, TTM YoY
FY25 Q2 -58.0%
FY25 Q3 -58.2%
FY25 Q4 -57.7%
FY26 Q1 -55.4%
FY26 Q2 32.4%
Operating margin (TTM) Gossamer Bio, Inc.
-400% -300% -200% -100% 0% FY24 Q2 FY24 Q4 FY25 Q2 FY25 Q4 FY26 Q2 Operating margin (TTM), FY24 Q2: -82.8% Operating margin (TTM), FY24 Q3: -69.1% Operating margin (TTM), FY24 Q4: -52.2% Operating margin (TTM), FY25 Q1: -44.0% Operating margin (TTM), FY25 Q2: -361.9% Operating margin (TTM), FY25 Q3: -365.1% Operating margin (TTM), FY25 Q4: -352.2% Operating margin (TTM), FY26 Q1: -321.9% Operating margin (TTM), FY26 Q2: -311.7% -311.7%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Operating margin (TTM)
FY24 Q2 -82.8%
FY24 Q3 -69.1%
FY24 Q4 -52.2%
FY25 Q1 -44.0%
FY25 Q2 -361.9%
FY25 Q3 -365.1%
FY25 Q4 -352.2%
FY26 Q1 -321.9%
FY26 Q2 -311.7%
FCF margin (TTM) Gossamer Bio, Inc.
-400% -300% -200% -100% 0% 100% FY24 Q2 FY24 Q4 FY25 Q2 FY25 Q4 FY26 Q2 FCF margin (TTM), FY24 Q2: -4.0% FCF margin (TTM), FY24 Q3: -1.3% FCF margin (TTM), FY24 Q4: -3.0% FCF margin (TTM), FY25 Q1: 7.3% FCF margin (TTM), FY25 Q2: -383.7% FCF margin (TTM), FY25 Q3: -359.8% FCF margin (TTM), FY25 Q4: -353.5% FCF margin (TTM), FY26 Q1: -306.7% FCF margin (TTM), FY26 Q2: -305.2% -305.2%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period FCF margin (TTM)
FY24 Q2 -4.0%
FY24 Q3 -1.3%
FY24 Q4 -3.0%
FY25 Q1 7.3%
FY25 Q2 -383.7%
FY25 Q3 -359.8%
FY25 Q4 -353.5%
FY26 Q1 -306.7%
FY26 Q2 -305.2%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-Q. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2022 Dec 2022 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025 LTM Jun 2026
Income
Revenue 0 0 115 48 53
EBITDA −217 −182 −59 −171 −166
Operating income −219 −184 −60 −171 −166
Net income −229 −180 −57 −170 −125
Diluted EPS −$2.71 −$1.18 −$0.25 −$0.75 −$0.49
Growth (year on year)
Revenue — — — −57.7% +32.4%
Margins
EBITDA margin — — −51.5% −352.2% −311.7%
Operating margin — — −52.2% −352.2% −311.7%
Net margin — — −49.3% −351.5% −235.0%
Free-cash-flow margin — — −3.0% −353.5% −305.2%
Cash flow
Cash from operations −187 −159 −3 −171 −163
Capital spending 0 0 0 0 0
Free cash flow −187 −159 −3 −171 −163
Stock-based pay 43 29 21 11 14
Free cash flow after stock pay −230 −188 −24 −182 −177
Balance sheet
Cash 112 32 46 38 41
Total debt 24 12 0 0 36
Net debt (negative = net cash) −88 −20 −46 −38 −5
Diluted shares 85m 153m 226m 229m 256m

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

1 of 3 checks passed · June 30, 2026
What it owns · $77m
Short-term assets $73mLonger-term assets $4m
What it owes, and who funded it · $171m
Short-term liabilities $138mLonger-term liabilities $33mShareholders' equity $-94m
  • Short-term assets cover short-term liabilities $73m of assets due within a year against $138m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $73m short-term assets against $33m of longer-dated liabilities.
  • More cash than debt Cash or debt not separately reported. Not assessable.
  • Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
  • Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
  • A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
  • Operating profit covers interest at least five times over Operating income of −$166m against $11m of interest.

From Gossamer Bio, Inc.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

Diluted share count
+14.3%
year over year
R&D spending
307.7%
of revenue
Days sales outstanding
42 days
receivables vs revenue

Competitors: side by side with peers

Closest by revenue in biotechnology
Last 12 months unless stated GOSS SIGA TNGX OCUL NKTR IVVD Median
Revenue, last 12 months $53m $54m $54m $52m $55m $58m $56m
Revenue growth, last 12 months 32.4% −70.1% 121.5% −8.1% −27.2% 26.3% 12.6%
Revenue growth, 3-year average — −18.1% 16.9% −1.6% −14.6% — 13.7%
Revenue growth, latest quarter −19.6% −49.5% −100.0% 0.1% −9.3% 21.2% 10.2%
Gross margin — 54.4% — 87.1% 100.0% — 82.9%
Operating margin −311.7% −20.8% −253.4% −603.0% −257.8% −192.8% −189.4%
Operating margin, 3-year average −252.1% 31.6% −404.1% −397.7% −189.3% <−999% −363.5%
Net margin −235.0% −5.2% −229.9% −579.1% −287.8% −183.9% −169.8%
Cash from operations / revenue −305.2% −37.6% −267.4% −457.7% −428.3% −185.8% −168.0%
Free-cash-flow margin −305.2% −38.2% −268.1% −490.1% −428.7% −187.9% −162.4%
Free-cash-flow margin, 3-year average −231.0% 23.6% −388.7% −318.3% −288.4% <−999% −310.0%
Stock pay / revenue 26.9% 6.5% 74.9% 102.4% 22.0% 19.2% 20.0%
Change in share count 14.3% 0.1% 21.8% 26.4% 6.2% 14.0% 8.2%

Median of all 184 companies we cover in biotechnology. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

184 biotechnology companies
Measure Company Peer median Rank
Revenue growth Growth 32.4% 12.6% 67 of 172
Change in growth rate Growth +87.9pp -0.1pp 20 of 172
Operating margin Profitability -311.7% -189.4% 105 of 175
Net margin Profitability -235.0% -157.3% 101 of 180
Free-cash-flow margin Cash generation -305.2% -145.4% 114 of 176
Stock pay as % of revenue Cash generation 26.9% 19.2% 100 of 179
Change in share count Balance sheet 14.3% 7.9% 103 of 156
Days sales outstanding Balance sheet 42 days 75 days 21 of 100

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Where the revenue comes from

Fiscal year to December 31, 2025
Products and services
Line of business Revenue Share YoY
Revenue From Contracts With Collaborators $48.5M 100.0% ▲ 101.8%
Licenses and services $0 0.0% ▼ 100.0%

From Gossamer Bio, Inc.'s 10-K filed March 17, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Who owns it

Funds buying and selling
Reported value
$62.7M
Institutions reporting
168
Shares held vs prior quarter
▲ 115.6%
Positions opened / closed
26 / 41

Top buyers and sellers, Q2 2026: 89 institutions bought and 85 sold ; the biggest buyer was D. E. Shaw & Co., Inc (+40.6M shares) and the biggest seller Blackrock, Inc (−9.2M). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
D. E. Shaw & Co., Inc. $6.7M 41.0M 10.8% ▲ 10417.7%
683 Capital Management, LLC $6.5M 39.2M 10.3% ▲ 684.0%
Deepcurrents Investment Group LLC $6M 37.7M 9.6% New
Context Capital Management, LLC $4.8M 28.9M 7.6% New
Worth Venture Partners, LLC $4.1M 25.0M 6.6% New
Kalehua Capital Management LLC $3.7M 22.3M 5.9% ▲ 25.9%
AQR Capital Management LLC $2.6M 15.6M 4.1% ▲ 54.3%
Gsa Capital Partners LLP $2.5M 15.0M 3.9% ▲ 360.5%
Wolverine Asset Management LLC $2.1M 12.9M 3.4% New
Renaissance Technologies LLC $1.9M 11.6M 3.1% ▲ 854.9%
Vanguard Capital Management LLC $1.6M 9.4M 2.5% ▲ 0.2%
Arch Venture Management, LLC $1.3M 8.1M 2.1% 0.0%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Gossamer Bio, Inc.'s complete shareholder register. Values are as reported by the filers ; 2 inconsistently scaled filing rows were excluded.

Insider trading activity

Full insider history and chart
Insider purchases History → $0 0 trades by 0 insiders, last 12 months Insider sales History → $0 0 trades by 0 insiders
Net ▲ $0 net buying

No open-market insider trades reported in the last 12 months.

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Next expected around October 28, 2026 estimated from the company's past filing pattern, not announced

  • August 13, 2026
  • July 27, 2026
  • May 18, 2026
  • March 17, 2026
  • November 5, 2025
  • August 5, 2025

Recent SEC filings

Data status

When each part of this page on Gossamer Bio, Inc. was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Gossamer Bio, Inc. in brief

What does Gossamer Bio, Inc. do?
Gossamer Bio, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.
What is Gossamer Bio, Inc.'s stock ticker?
Gossamer Bio, Inc. trades under the ticker GOSS on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Gossamer Bio, Inc.'s revenue, and how fast is it growing?
Over its most recent trailing twelve months, Gossamer Bio, Inc. reported revenue of $53.3M, 32.4% higher than a year earlier, according to its SEC filings.
What is Gossamer Bio, Inc.'s free cash flow?
Gossamer Bio, Inc.'s free-cash-flow margin is -305.2% of revenue over the trailing twelve months, ranking 114 of the 176 biotechnology companies we cover.
Who are Gossamer Bio, Inc.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are D. E. Shaw & Co., Inc., 683 Capital Management, LLC and Deepcurrents Investment Group LLC. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
What is Gossamer Bio, Inc.'s market cap?
On November 2, 2026, Gossamer Bio, Inc.'s market capitalisation was about $2.4B and net debt of -$5M. Market figures come from third-party market data and may be delayed.
Who are Gossamer Bio, Inc.'s competitors?
In our Biotechnology peer group, the companies closest to Gossamer Bio, Inc. are Siga Technologies Inc, Tango Therapeutics, Inc., Ocular Therapeutix, Inc, Nektar Therapeutics and Invivyd, Inc. The side-by-side comparison below sets their revenue, margins and growth against Gossamer Bio, Inc.'s.
When is Gossamer Bio, Inc.'s next earnings date?
Around November 4, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Gossamer Bio, Inc. announces its own schedule.